Merck KGaA reported FY 2025 net sales of EUR 21.1 billion (organic growth +3.1%; reported -0.3%), with foreign exchange effects of -3.7%. FY 2025 EBITDA pre was EUR 6.1 billion (organic growth +5.6%), and the EBITDA pre margin was 28.9%. FY 2025 profit after tax was EUR 2.6 billion (-6.1%) and earnings per share were EUR 6.00 (-6.1%); earnings per share pre were EUR 8.34 (-3.4%). Operating cash flow was EUR 3.9 billion (-14.3%). For Q4 2025, net sales grew organically by +2.6% while reported net sales fell -3.1%, and reported EBITDA pre declined -3.2% while growing +3.1% organically. By sector in FY 2025, Life Science net sales were EUR 9.0 billion (organic +4.0%), driven by Process Solutions at EUR 3.8 billion (organic +10.7%); Healthcare net sales were EUR 8.6 billion (organic +3.7%) with Mavenclad at EUR 1.2 billion (organic +16.6%) and Pergoveris at EUR 329 million (organic +22.6%); Electronics net sales were EUR 3.5 billion (organic -0.6%) and EBITDA pre was EUR 833 million (-14.1%), with the company citing one-time effects in Q2 2025 and lower sales in Delivery Systems & Services. Merck KGaA proposed an unchanged dividend of EUR 2.20 per share. For 2026, it guided to net sales of EUR 20.0 billion to EUR 21.1 billion and EBITDA pre of EUR 5.5 billion to EUR 6.0 billion, assuming no U.S. sales of Mavenclad from March 2026 amid generic competition and excluding potential upside from a U.S. launch of Pergoveris. Corporate updates included the completed acquisition of SpringWorks and the divestment of Surface Solutions, plus a EUR 500 million investment in a Semiconductor Solutions mega-site in Kaohsiung, Taiwan, and a 60% reduction in absolute Scope 1 and 2 greenhouse gas emissions versus the 2020 baseline by end-2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.